Botulinum neurotoxin: from molecular pathogenesis to emerging countermeasures.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic review methodology or original human data
PubMed 42228319 · doi:10.1007/s44446-026-00090-2
What was done
This narrative review synthesized literature on botulinum neurotoxins (BoNTs), covering their structural and molecular mechanisms, clinical manifestations, current treatment approaches, and emerging preclinical therapies including small-molecule inhibitors, antibody-based therapies, intracellular clearance methods, and gene- and RNA-based platforms.
What was found
The review notes that BoNT is highly potent with an estimated human lethal dose (LD50) of approximately 1 ng/kg, blocking acetylcholine release via SNARE protein cleavage. Standard antitoxin therapy only neutralizes extracellular circulating toxin and cannot target intracellular BoNT, often resulting in prolonged mechanical ventilation and rehabilitation. Specific quantitative outcomes or comparative effect sizes for emerging agents are not reported in the abstract.
Why it matters
Current clinical care lacks methods to reverse paralysis once botulinum toxin enters nerve terminals. Clarifying intracellular countermeasure pipelines highlights viable translational paths for biodefense and clinical management.
Limits
This is a narrative review without systematic search methods, primary clinical data, or quantitative comparative metrics in the abstract. The novel countermeasures discussed remain in preclinical development and have not demonstrated clinical safety or efficacy in humans.
Cited by
- contradicts Mercury is the second most potent toxin on Earth after plutonium.